Regimen_ID,Name,Description,Category,Line_of_Therapy,Schedule,Cycles,Mechanism_of_Action,Overall_Response_Rate,Progression_Free_Survival,ECOG_Status_Required,Contraindications,Clinical_Trials
FOLFOX-mCRC-1L,FOLFOX,Oxaliplatin + 5-FU + Leucovorin for metastatic colorectal cancer,metastatic,first-line,Every 2 weeks,12,DNA crosslinking + antimetabolite,45-50%,9.4 months,"0,1,2","Severe neuropathy; severe renal impairment",NCT12345678
FOLFIRI-mCRC-2L,FOLFIRI,Irinotecan + 5-FU + Leucovorin for second-line metastatic colorectal cancer,metastatic,second-line,Every 2 weeks,12,Topoisomerase I inhibition + antimetabolite,35-40%,6.2 months,"0,1,2","Severe diarrhea history; UGT1A1*28 homozygous",NCT23456789
CAPOX-adj,CAPOX,Capecitabine + Oxaliplatin adjuvant therapy,adjuvant,first-line,Every 3 weeks,8,Oral fluoropyrimidine + platinum agent,N/A,N/A,"0,1","DPD deficiency; severe renal impairment",NCT34567890
FOLFOXIRI-mCRC-1L,FOLFOXIRI + Bevacizumab,Intensive triplet therapy with anti-VEGF for fit patients,metastatic,first-line,Every 2 weeks,12,Multi-target cytotoxic + angiogenesis inhibition,65-70%,12.3 months,"0,1","Age >75; significant comorbidities",NCT45678901
REGORAFENIB-mCRC-3L,Regorafenib,Multi-kinase inhibitor for refractory metastatic colorectal cancer,metastatic,third-line,Daily for 21 days every 28 days,Until progression,Multi-kinase inhibition,8-10%,1.9 months,"0,1,2","Severe liver dysfunction; uncontrolled hypertension",NCT56789012